Tissue-Engineered Skeletal Muscle Organoids for Reversible Gene Therapy
- 10 November 1996
- journal article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 7 (17) , 2195-2200
- https://doi.org/10.1089/hum.1996.7.17-2195
Abstract
Genetically modified murine skeletal myoblasts were tissue engineered in vitro into organ-like structures (organoids) containing only postmitotic myofibers secreting pharmacological levels of recombinant human growth hormone (rhGH). Subcutaneous organoid implantation under tension led to the rapid and stable appearance of physiological sera levels of rhGH for up to 12 weeks, whereas surgical removal led to its rapid disappearance. Reversible delivery of bioactive compounds from postmitotic cells in tissue engineered organs has several advantages over other forms of muscle gene therapy.Keywords
This publication has 26 references indexed in Scilit:
- Long-Term Expression of the Biologically Active Growth Hormone in Genetically Modified Fibroblasts after Implantation into a Hypophysectomized RatHuman Gene Therapy, 1995
- Muscle Delivery of Human Kallikrein Gene Reduces Blood Pressure in Hypertensive RatsHypertension, 1995
- Correction of the Growth Defect in Dwarf Mice with Nonautologous Microencapsulated Myoblasts—An Alternate Approach to Somatic Gene TherapyHuman Gene Therapy, 1995
- Persistent Erythropoiesis by Myoblast Transfer of Erythropoietin cDNAHuman Gene Therapy, 1994
- Tissue EngineeringScience, 1993
- Systemic Delivery of Recombinant Proteins by Genetically Modified MyoblastsScience, 1991
- Folding of Circularly Permuted Transfer RNAsScience, 1991
- Human dystrophin expression in mdx mice after intramuscular injection of DNA constructsNature, 1991
- Direct Gene Transfer into Mouse Muscle in VivoScience, 1990